R
Richard Bittman
Researcher at Pharmacia
Publications - 6
Citations - 4734
Richard Bittman is an academic researcher from Pharmacia. The author has contributed to research in topics: Spironolactone & Eplerenone. The author has an hindex of 4, co-authored 5 publications receiving 4498 citations. Previous affiliations of Richard Bittman include National Cheng Kung University & Indian Institute of Technology Delhi.
Papers
More filters
Journal ArticleDOI
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
Bertram Pitt,Willem J. Remme,Faiez Zannad,James D. Neaton,Felipe Martinez,Barbara Roniker,Richard Bittman,Steve Hurley,Jay H. Kleiman,Marjorie Gatlin +9 more
TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI
The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction
Bertram Pitt,Bertram Pitt,Bertram Pitt,Gordon H. Williams,Gordon H. Williams,Gordon H. Williams,Willem Remme,Willem Remme,Willem Remme,Felipe Martinez,Felipe Martinez,Felipe Martinez,Jose Lopez-Sendon,Jose Lopez-Sendon,Jose Lopez-Sendon,Faiez Zannad,Faiez Zannad,Faiez Zannad,James D. Neaton,James D. Neaton,James D. Neaton,Barbara Roniker,Barbara Roniker,Barbara Roniker,Steve Hurley,Steve Hurley,Steve Hurley,Dan Burns,Dan Burns,Dan Burns,Richard Bittman,Richard Bittman,Richard Bittman,Jay H. Kleiman,Jay H. Kleiman,Jay H. Kleiman +35 more
TL;DR: If the hypothesis being tested in the EPHESUS trial proves correct, eplerenone has the potential to be used in a broad population to prevent progressive left ventricular remodeling, ventricular fibrosis, malignant arrhythmias, non-fatal AMI, and sudden cardiac death.
Journal ArticleDOI
Efficacy and Safety of the Selective Aldosterone Blocker Eplerenone in Japanese Patients With Hypertension: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study
Takao Saruta,Shigeru Kageyama,Toshio Ogihara,Kunio Hiwada,Masayo Ogawa,Kazuji Tawara,Marjorie Gatlin,Susan Garthwaite,Richard Bittman,Jeffrey Patrick +9 more
TL;DR: Eplerenone offers significant blood pressure reduction with good tolerability in Japanese patients with hypertension, including those with low‐renin hypertension.
Journal ArticleDOI
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Norman K. Hollenberg,Gordon H. Williams,Richard B. Anderson,Kasem S. Akhras,Richard Bittman,Scott Krause +5 more
TL;DR: The aldosterone antagonist eplerenone is substantially better tolerated than the widely used calcium-channel blocking agent amlodipine, with comparable reductions in systolic blood pressure.
Journal ArticleDOI
The EPHESUS trial: evaluation of eplerenone in the subgroup of patients with baseline left ventricular ejection fraction ≤30%
Bertram Pitt,Faiez Zannad,Richard Bittman,Myrlene Staten,Jeffrey L. Anderson,Mihai Gheorghiade,Dirk-Jan van Veldhuisen,Jay H. Kleiman +7 more
TL;DR: The EPHESUS Trial: Evaluation of Eplerenone in the Subgroup of Patients with Baseline Left Ventricular Ejection Fraction 30% evaluated the safety and effectiveness of this drug in patients with a history of heart attack.